In T-cell acute lymphoblastic leukemia cells with both MCL1 and BCL2 overexpression, combination therapy with inhibitors of both MCL1 (S63845) and BCL2 (venetoclax) is highly efficacious[152]. Here, MCL1 is linked to T-cell acute lymphoblastic leukemia.